Population pharmacokinetics of lopinavir/ritonavir (LPVr) in HIV-1-infected patients

被引:0
|
作者
Crommentuyn, KML
Kappelhoff, BS
Mulder, JW
Mairuhu, ATA
van Gorp, ECM
Meenhorst, PL
Huitema, ADR
Beijnen, JH
机构
[1] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands
[3] Univ Utrecht, Fac Pharmaceut Sci, Dept Biomed Anal, Div Drug Toxicol, Utrecht, Netherlands
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:609 / 610
页数:2
相关论文
共 50 条
  • [1] Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 378 - 389
  • [2] The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients
    Crommentuyn, KML
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    ANTIVIRAL THERAPY, 2004, 9 (05) : 779 - 785
  • [3] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
  • [4] Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients
    Kappelhoff, BS
    Huitema, ADR
    Sankatsing, SUC
    Meenhorst, PL
    Van Gorp, ECM
    Mulder, JW
    Prins, JM
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (03) : 276 - 286
  • [5] Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children
    van der Lee, Manon
    Verweel, Gwenda
    de Groot, Ronald
    Burger, David
    ANTIVIRAL THERAPY, 2006, 11 (04) : 439 - 445
  • [6] Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
    Foissac, Frantz
    Blanche, Stephane
    Dollfus, Catherine
    Hirt, Deborah
    Firtion, Ghislaine
    Laurent, Corinne
    Treluyer, Jean-Marc
    Urien, Saik
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) : 940 - 947
  • [7] Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients
    Lopez-Cortes, Luis F.
    Ruiz-Valderas, Rosa
    Sanchez-Rivas, Elena
    Lluch, Amparo
    Gutierrez-Valencia, Alicia
    Torres-Cornejo, Almudena
    BenMarzouk-Hidalgo, Omar J.
    Viciana, Pompeyo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) : 3746 - 3751
  • [8] Concentration-response Model of Lopinavir/Ritonavir in HIV-1-infected Pediatric Patients
    Bouazza, Naim
    Urien, Saik
    Blanche, Stephane
    Hirt, Deborah
    Foissac, Frantz
    Benaboud, Sihem
    Treluyer, Jean-Marc
    Frange, Pierre
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : E213 - E218
  • [9] Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients
    van Heeswijk, RPG
    Bourbeau, M
    Seguin, I
    Giguere, P
    Garber, GE
    Cameron, DW
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (04) : 398 - 404
  • [10] Population Pharmacokinetics of Emtricitabine in HIV-1-Infected Adult Patients
    Valade, Elodie
    Treluyer, Jean-Marc
    Bouazza, Naim
    Ghosn, Jade
    Foissac, Frantz
    Benaboud, Sihem
    Fauchet, Floris
    Viard, Jean-Paul
    Urien, Saik
    Hirt, Deborah
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2256 - 2261